Overview

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Status:
Completed

Trial end date:
2019-02-13

Target enrollment:

Participant gender:

Summary

This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.

Phase:

Phase 2

Details

Lead Sponsor:

Envisia Therapeutics

Treatments:

Maleic acid
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Travoprost